Thomas Sweeney Heard

Array ( [id] => 16663898 [patent_doc_number] => 10933120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => Compositions of GLP-1 peptides and preparation thereof [patent_app_type] => utility [patent_app_number] => 14/386589 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16673 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386589 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9736211 [patent_doc_number] => 20140271923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions' [patent_app_type] => utility [patent_app_number] => 13/815664 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 30778 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13815664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9069294 [patent_doc_number] => 20130261050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-03 [patent_title] => 'ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION' [patent_app_type] => utility [patent_app_number] => 13/827125 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13902 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13827125 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9122035 [patent_doc_number] => 20130288957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-31 [patent_title] => 'ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS' [patent_app_type] => utility [patent_app_number] => 13/800190 [patent_app_country] => US [patent_app_date] => 2013-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 14648 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13800190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10695041 [patent_doc_number] => 20160041188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'PEPTIDE WITH GOLD BINDING AND EGFR RECEPTOR AFFINITY AND SAME ATTACHED TO GOLD NANOSTRUCTURE' [patent_app_type] => utility [patent_app_number] => 14/386269 [patent_app_country] => US [patent_app_date] => 2013-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 3910 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10634473 [patent_doc_number] => 09351960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-31 [patent_title] => 'Agent for the treatment of viral hepatitis C' [patent_app_type] => utility [patent_app_number] => 14/384737 [patent_app_country] => US [patent_app_date] => 2013-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8943 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14384737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9095129 [patent_doc_number] => 20130274439 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-17 [patent_title] => 'ANTIVIRAL COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 13/794389 [patent_app_country] => US [patent_app_date] => 2013-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67101 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13794389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8915907 [patent_doc_number] => 20130177531 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-11 [patent_title] => 'Inhibitors of Serine Proteases' [patent_app_type] => utility [patent_app_number] => 13/780373 [patent_app_country] => US [patent_app_date] => 2013-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 20332 [patent_no_of_claims] => 68 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13780373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9685265 [patent_doc_number] => 20140242029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-28 [patent_title] => 'COMBINATION THERAPY FOR TREATING HCV INFECTION IN AN HCV-HIV COINFECTED PATIENT POPULATION' [patent_app_type] => utility [patent_app_number] => 13/778725 [patent_app_country] => US [patent_app_date] => 2013-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7706 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13778725 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11224516 [patent_doc_number] => 09452225 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-27 [patent_title] => 'GLP-1 prodrugs' [patent_app_type] => utility [patent_app_number] => 14/379445 [patent_app_country] => US [patent_app_date] => 2013-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 36957 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14379445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9232815 [patent_doc_number] => 08598118 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-03 [patent_title] => 'Hepatocyte growth factor mimics as therapeutic agents' [patent_app_type] => utility [patent_app_number] => 13/768497 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 59 [patent_no_of_words] => 37922 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 4 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13768497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9812092 [patent_doc_number] => 20150024037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-22 [patent_title] => 'Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making' [patent_app_type] => utility [patent_app_number] => 14/378805 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 49 [patent_no_of_words] => 20604 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14378805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8904773 [patent_doc_number] => 20130172276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-07-04 [patent_title] => 'PROCESSES AND INTERMEDIATES' [patent_app_type] => utility [patent_app_number] => 13/767577 [patent_app_country] => US [patent_app_date] => 2013-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28388 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13767577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9793288 [patent_doc_number] => 20150005233 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-01 [patent_title] => 'TREATMENT OF HYPOGLYCEMIA' [patent_app_type] => utility [patent_app_number] => 14/377475 [patent_app_country] => US [patent_app_date] => 2013-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26460 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14377475 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8842010 [patent_doc_number] => 20130137638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-30 [patent_title] => 'CONJUGATED FACTOR VIII MOLECULES' [patent_app_type] => utility [patent_app_number] => 13/759261 [patent_app_country] => US [patent_app_date] => 2013-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10796 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13759261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9817715 [patent_doc_number] => 08927501 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-01-06 [patent_title] => 'αvβ6 peptide ligands and their uses' [patent_app_type] => utility [patent_app_number] => 13/743714 [patent_app_country] => US [patent_app_date] => 2013-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 18642 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 8 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13743714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10946899 [patent_doc_number] => 20140349921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-27 [patent_title] => 'HCV NS3 PROTEASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/365329 [patent_app_country] => US [patent_app_date] => 2013-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9733 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14365329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9294085 [patent_doc_number] => 20140037719 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-06 [patent_title] => 'STABILIZED PHARMACEUTICAL FORMULATIONS OF A POTENT HCV INHIBITOR' [patent_app_type] => utility [patent_app_number] => 13/738057 [patent_app_country] => US [patent_app_date] => 2013-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 8818 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13738057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10380667 [patent_doc_number] => 20150265674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'POLY-GLUTAMIC ACID ANTI-ANTHRAX COMPOSITIONS AND METHODS FOR USING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/738911 [patent_app_country] => US [patent_app_date] => 2013-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9238 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13738911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8815130 [patent_doc_number] => 20130116175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'REVERSIBLE PEGYLATED DRUGS' [patent_app_type] => utility [patent_app_number] => 13/731989 [patent_app_country] => US [patent_app_date] => 2012-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 37451 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13731989 [rel_patent_id] =>[rel_patent_doc_number] =>)